Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic

por Mazar, Andrew P., Ahn, Richard W., O'Halloran, Thomas V.
Publicado 2011

Regulation of intrapleural fibrinolysis by urokinase-α-macroglobulin complexes in tetracycline-induced pleural injury in rabbits

por Komissarov, Andrey A., Mazar, Andrew P., Koenig, Kathy, Kurdowska, Anna K., Idell, Steven
Publicado 2009

The Many Spaces of uPAR: Delivery of Theranostic Agents and Nanobins to Multiple Tumor Compartments through a Single Target

por O'Halloran, Thomas V., Ahn, Richard, Hankins, Patrick, Swindell, Elden, Mazar, Andrew P.
Publicado 2013

Targeting SOD1 reduces experimental non–small-cell lung cancer

por Glasauer, Andrea, Sena, Laura A., Diebold, Lauren P., Mazar, Andrew P., Chandel, Navdeep S.
Publicado 2013

The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma

por LEE, KRISTY, HART, MATTHEW R., BRIEHL, MARGARET M., MAZAR, ANDREW P., TOME, MARGARET E.
Publicado 2014

uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions

por Mahmood, Niaz, Arakelian, Ani, Khan, Haseeb Ahmed, Tanvir, Imrana, Mazar, Andrew P., Rabbani, Shafaat A.
Publicado en Bone Res (2020)

Regulation of Urokinase Receptor Expression by p53: Novel Role in Stabilization of uPAR mRNA

por Shetty, Sreerama, Velusamy, Thirunavukkarasu, Idell, Steven, Shetty, Praveenkumar, Mazar, Andrew P., Bhandary, Yashodhar P., Shetty, Rashmi S.
Publicado 2007

α5β1 Integrin Signaling Mediates Oxidized LDL-Induced Inflammation and Early Atherosclerosis

por Yurdagul, Arif, Green, Jonette, Albert, Patrick, McInnis, Marshall C., Mazar, Andrew P., Orr, A. Wayne
Publicado 2014

The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin’s Lymphoma Cells and Human Xenograft Models

por Ravi, Dashnamoorthy, Bhalla, Savita, Gartenhaus, Ronald B, Crombie, Jennifer, Kandela, Irawati, Sharma, Jaya, Mazar, Andrew, Evens, Andrew M.
Publicado en Clin Cancer Res (2014)

Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma

por Dong, Ruifen, Qiang, Wenan, Guo, Haiyang, Xu, Xiaofei, Kim, J. Julie, Mazar, Andrew, Kong, Beihua, Wei, Jian-Jun
Publicado en J Hematol Oncol (2016)

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents

por Karmali, Reem, Chukkapalli, Vineela, Gordon, Leo I., Borgia, Jeffrey A., Ugolkov, Andrey, Mazar, Andrew P., Giles, Francis J.
Publicado en Oncotarget (2017)

The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells

por Tucker, Torry A., Dean, Candice, Komissarov, Andrey A., Koenig, Kathy, Mazar, Andrew P., Pendurthi, Usha, Allen, Timothy, Idell, Steven
Publicado 2010

Virtual High-Throughput Screening To Identify Novel Activin Antagonists

por Zhu, Jie, Mishra, Rama K., Schiltz, Gary E., Makanji, Yogeshwar, Scheidt, Karl A., Mazar, Andrew P., Woodruff, Teresa K.
Publicado en J Med Chem (2015)

Structural Basis of Interaction between Urokinase-Type Plasminogen Activator and Its Receptor

por Barinka, Cyril, Parry, Graham, Callahan, Jennifer, Shaw, David E., Kuo, Alice, Bdeir, Khalil, Cines, Douglas B., Mazar, Andrew, Lubkowski, Jacek
Publicado 2006

Melanoma cells block PEDF production in fibroblasts to induce the tumor-promoting phenotype of cancer-associated fibroblasts

por Nwani, Nkechiyere G, Deguiz, Maria L, Jimenez, Benilde, Vinokour, Elena, Dubrovskyi, Oleksii, Ugolkov, Andrey, Mazar, Andrew P, Volpert, Olga V
Publicado en Cancer Res (2016)

Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer

por Ugolkov, Andrey V., Matsangou, Maria, Taxter, Timothy J., O'Halloran, Thomas V., Cryns, Vincent L., Giles, Francis J., Mazar, Andrew P.
Publicado en Oncol Lett (2018)

Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer

por Anraku, Tsutomu, Kuroki, Hiroo, Kazama, Akira, Bilim, Vladimir, Tasaki, Masaaki, Schmitt, Daniel, Mazar, Andrew, Giles, Francis J., Ugolkov, Andrey, Tomita, Yoshihiko
Publicado en Int J Mol Med (2020)

An Anti-Urokinase Plasminogen Activator Receptor Antibody (ATN-658) Blocks Prostate Cancer Invasion, Migration, Growth, and Experimental Skeletal Metastasis In Vitro and In Vivo

por Rabbani, Shafaat A, Ateeq, Bushra, Arakelian, Ani, Valentino, Maria Luisa, Shaw, David E, Dauffenbach, Lisa M, Kerfoot, Christopher A, Mazar, Andrew P
Publicado 2010

Copper Chelator ATN-224 Induces Peroxynitrite-Dependent Cell Death in Hematological Malignancies

por Lee, Kristy, Briehl, Margaret M., Mazar, Andrew P., Batinic-Haberle, Ines, Reboucas, Julio S., Glinsmann-Gibson, Betty, Rimsza, Lisa M., Tome, Margaret E.
Publicado 2013

Targeting the Urokinase Plasminogen Activator Receptor With a Monoclonal Antibody Impairs the Growth of Human Colorectal Cancer in the Liver

por Van Buren, George, Gray, Michael J., Dallas, Nikolaos A., Xia, Ling, Lim, Sherry J., Fan, Fan, Mazar, Andrew P., Ellis, Lee M.
Publicado en Cancer (2009)